A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake in Pacira BioSciences, has launched a proxy contest to replace the board. DOMA argues that CEO Frank Lee and the board have grossly underperformed, citing a -28% total return since Lee’s appointment and persistent failure to mitigate patent litigation risks for core asset EXPAREL.
Key figures
- Stock return 1yr
- -12%
- Stock return 2yr
- -25%
- Stock return 5yr
- -64%
- Stock return ytd
- -11%
- Stock return 10yr
- -46%
- Activist stake pct
- 7.5%
- Ceo compensation 2yr
- $28 million
- Activist stake shares
- 2777794
- Exparel revenue share
- >80%
- Stock return since ceo
- -28%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.